Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1522282 (
EMT
)
2,868
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The centrosome plays a key role in cancer invasion and metastasis. However, it is unclear how abnormal centrosome numbers are regulated when prostate cancer (PCa) cells become metastatic.
CP110
was previously described for its contribution of centrosome amplification (CA) and early development of aggressive cell behaviour. However its regulation in metastatic cells remains unclear. Here we identified miR-129-3p as a novel metastatic microRNA.
CP110
was identified as its target protein. In PCa cells that have metastatic capacity,
CP110
expression was repressed by miR-129-3p. High miR-129-3p expression levels increased cell invasion, while increasing
CP110
levels decreased cell invasion. Overexpression of
CP110
in metastatic PCa cells resulted in a decrease in the number of metastasis. In tissues of PCa patients, low
CP110
and high miR-129-3p expression levels correlated with metastasis, but not with the expression of genes related to
EMT
. Furthermore, overexpression of
CP110
in metastatic PCa cells resulted in excessive-CA (E-CA), and a change in F-actin distribution which is in agreement with their reduced metastatic capacity. Our data demonstrate that miR-129-3p functions as a CA gatekeeper in metastatic PCa cells by maintaining pro-metastatic centrosome amplification (CA) and preventing anti-metastatic E-CA.
...
PMID:miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110. 2691 38